About United Therapeutics Corporation
United Therapeutics is a biotechnology company focused on therapeutics for life-threatening diseases. The company is active in the three therapeutic areas of cardiovascular medicine, infectious disease and oncology.
The company has five therapeutic platforms prostacyclin analogs, oncology, iminosugars, arginine formulations, and telemedicine.
Much of United Therapeutics' resources are focused on cardiovascular health, including developing analogs of the endogenous hormone prostacyclin for the treatment of pulmonary hypertension and critical limb ischemia, a variety of telecardiology services for patients with an array of possible cardiac arrhythmias, and arginine supplement therapy. United Therapeutics' second principal focus is oncology and the company is undertaking the largest ever pivotal trial of a potential medicine for preventing the recurrence of ovarian cancer. This medicine is part of a family of similar therapies licensed to United Therapeutics which are designed to combat a number of other cancers. United Therapeutics' third focus is in the field of infectious disease, where the company is targeting hepatitis C and hepatitis B with unique glycobiology compounds.
The theme of United Therapeutics is "Medicines for Life" because all of our therapeutics are geared to life-threatening illnesses.
The company’s mission is carried out using corporate partners for product sales and academic affiliates for research, and the company generally retains all rights to the products it develops.
This strategy streamlines company overhead and enables company employees to concentrate on clinical trials, regulatory approvals and business development.
United Therapeutics Corporation's common stock began trading on the Nasdaq Stock Market's Nasdaq National Market on June 17, 1999 under the symbol "UTHR."
United Therapeutics is part of the Russel 3000 Index and the iShares Nasdaq Biotechnology Index (NBI).